

AEGIS AI QUANT INTELLIGENCE

Premium Equity Research Report

Rapid Dose Therapeutics Corp.

CSE: DOSE | OTCQB: RDTCF



Brand Positioning: Aegis AI Quant Intelligence Brand

Theme: Dark navy, neon teal, and gold premium format

Report Focus: platform scalability, catalyst map, balance-sheet risk, and scenario valuation

Reference Price	TTM Revenue	Revenue Growth	Shares Out.
CAD \$0.115	CAD 2.78M	72.8%	131.9M

Investment Stance: Speculative Buy / High-Risk Catalyst Watch

Rapid Dose now has a sharper commercial story than many micro-cap platform peers: a proprietary oral thin-film delivery system, a live nicotine regulatory pathway in Canada, a Brazil medical cannabis launch, and a fresh OTCQB listing that broadens U.S. investor access. The counterweight is still financing risk, dilution sensitivity, and the need to convert technical progress into repeatable revenue.

1. Executive Summary

Rapid Dose Therapeutics develops oral thin-film delivery products under its QuickStrip™ platform across nicotine, cannabinoid, consumer wellness, and pharmaceutical-style applications. The near-term thesis is not about current profitability; it is about whether management can translate product approvals, patents, and partnerships into a durable commercial inflection before capital structure pressure overwhelms equity upside.

Why the story matters now: the company announced a commercial launch of QuickStrip™ medical cannabis in Brazil in February 2026, began trading on the OTCQB in February 2026, and highlighted both a patent win and ongoing clinical/cannabinoid work in March 2026. Those events collectively make the stock more catalyst-driven than it was a year earlier.



2. Business Model and Catalyst Monitor

Platform	QuickStrip™ oral thin-film drug delivery system designed for fast, precise dosing across multiple categories.
Commercial Lines	NicStrip™ nicotine, medical cannabis formats, consumer wellness strips, and white-label / development collaborations.
Current Catalyst Stack	Brazil launch, OTCQB access, nicotine patent visibility, PK-study / Health Canada pathway, and broader IP-led partnering.
Key Risk	Execution must outrun balance-sheet strain, debt servicing, and ongoing dilution risk.

Catalyst	Status / Interpretation
Health Canada nicotine review	Submission was filed in August 2025; any regulatory feedback, deficiency response, or approval update could materially re-rate the stock.
PK nicotine study	Management said the study was ongoing in the October 2025 update; data or positioning commentary could affect commercial credibility.
Brazil cannabis rollout	The February 2026 launch creates a real-world commercialization test for the QuickStrip platform.
Patent / IP momentum	March 2026 patent news strengthens the company's licensing and strategic-partner narrative.


3. Financial Trend Review

Reported fundamentals show a genuine top-line rebound but not yet a self-funded operating model. Revenue improved materially into FY25 and the trailing twelve months, while operating losses, negative free cash flow, and a rising share count continue to limit the market's willingness to underwrite an aggressive multiple.



4. Capital Structure and Dilution Review

The platform story is investable only if dilution stays manageable. Basic shares climbed from 78 million in FY21 to 125 million in FY25, while the investor centre lists 131.9 million shares outstanding and 168.7 million fully diluted. That dilution arc is the central reason the name should be treated as a catalyst trade or speculative platform build rather than a conventional quality compounder.



Selected KPI	Latest Figure
Market cap	CAD 14.87M
TTM revenue	CAD 2.78M
TTM gross margin	50.44%
TTM free cash flow	CAD -0.87M
Cash & equivalents	CAD 0.11M
Q3 FY26 revenue	CAD 0.657M
Q3 FY26 net loss	CAD -1.14M

5. Aegis Scenario Valuation

Because Rapid Dose is still loss-making and early in commercial scale-up, a scenario price-to-sales approach is more defensible than a traditional DCF. The model below is intentionally simple and meant to frame outcomes rather than imply precision.

Scenario	FY27 Revenue	P/S Multiple	Implied Mkt Cap	Implied Price
Bear	CAD 3.5M	3.0x	CAD 10.5M	CAD \$0.08
Base	CAD 5.0M	4.5x	CAD 22.5M	CAD \$0.17
Bull	CAD 7.0M	6.0x	CAD 42.0M	CAD \$0.32

Aegis Base Case: CAD \$0.17 per share. That sits above the reference price of CAD \$0.115, but the margin of safety is not wide enough to ignore execution and financing risks. Upside is therefore tied to newsflow and commercialization proof, not to static balance-sheet strength.

Interpretation: the equity can work if one or more of the following occurs within the next reporting cycle: a credible nicotine regulatory update, stronger monetization from Brazil or other commercial channels, or additional IP / partner wins that persuade the market to pay a higher sales multiple.

6. Risk Matrix and Final Verdict

Risk	Why it matters
Dilution	Historical share growth and financing structures can mute upside even when operating news improves.
Regulatory timing	Nicotine and cannabis pathways can slip or require added evidence, delaying monetization.
Commercial conversion	Platform validation is not the same as repeatable distribution and sell-through.
Liquidity / scale	Micro-cap trading conditions can amplify volatility around news and funding needs.

Final Verdict: Speculative Buy / Catalyst Watch. Rapid Dose has enough platform, IP, and market-access momentum to justify premium speculative attention, but not enough financial durability to justify a relaxed underwriting standard. This is best framed as an event-driven AI quant intelligence name where confirmation of commercial traction is the unlock.

Aegis AI Composite View:

- Growth Trajectory: 7/10
- Balance Sheet Durability: 3/10
- Catalyst Intensity: 8/10
- Dilution Risk: 3/10
- Speculative Opportunity Score: 6.5/10

Appendix | Sources and Method

This report uses company press releases and investor-centre disclosures for corporate developments and share structure, together with StockAnalysis / S&P; Global Market Intelligence summary tables for price and selected historical financial metrics. The scenario valuation model is illustrative and not a prediction or investment recommendation.

Primary source set embedded in analysis: investor centre updates, nicotine submission and business-update releases, OTCQB / Brazil launch press releases, and recent market-data summaries for revenue, margins, free cash flow, cash, market capitalization, and shares.

Prepared in the Aegis AI Quant Intelligence format for ongoing stock-report coverage.